CSIMarket



Worst Performing Stocks In Major Pharmaceutical Preparations Industry During The Last 30 Days



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares are up by 1.84% on average, in Major Pharmaceutical Preparations Industry during the last 30 days.

Here are the Worst performing stocks in Major Pharmaceutical Preparations Industry.




VSTM

$3.47

$-9.6500 -73.55%
Last 30 Days


VSTM

$3.47

$-9.6500 -73.55%



Verastem Inc

Verastem Inc stock dropped -73.55% during the last 30 days.


Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 93.107 mill. $ - mill. $ -105.516 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 93.107 mill.


$ - mill.


$ -105.516 mill.

Employees Shares Outstanding P/E

73


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ANL

$3.37

$-9.3400 -73.49%
Last 30 Days


ANL

$3.37

$-9.3400 -73.49%



Adlai Nortye Ltd

Adlai Nortye Ltd stock dropped -73.49% during the last 30 days.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 146.063 mill. $ 5.000 mill. $ -104.871 mill. 43 mill. - Y/Y 0.00 %
Market Cap. Revenues TTM Net Income TTM

$ 146.063 mill.


$ 5.000 mill.


$ -104.871 mill.

Employees Shares Outstanding P/E

-


43 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 0.00 %


MRQ Y/Y - %



CNSP

$2.79

$-7.2100 -72.10%
Last 30 Days


CNSP

$2.79

$-7.2100 -72.10%



Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc stock dropped -72.10% during the last 30 days.


CNS Pharmaceuticals Inc*s business model focuses on developing innovative solutions and treatments for central nervous system diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 24.308 mill. $ 0.034 mill. $ -17.464 mill. 9 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 24.308 mill.


$ 0.034 mill.


$ -17.464 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SBFM

$0.33

$-0.5624 -63.02%
Last 30 Days


SBFM

$0.33

$-0.5624 -63.02%



Sunshine Biopharma Inc

Sunshine Biopharma Inc shares declined -63.02% during the last 30 days.


Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.002 mill. $ 26.740 mill. $ -4.087 mill. 0 mill. - Y/Y 54.09 %
Market Cap. Revenues TTM Net Income TTM

$ 0.002 mill.


$ 26.740 mill.


$ -4.087 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 54.09 %


MRQ Y/Y - %



JAGX

$4.05

$-6.1540 -60.31%
Last 30 Days


JAGX

$4.05

$-6.1540 -60.31%



Jaguar Health Inc

Jaguar Health Inc stock went down -60.31% during the last 30 days.


Jaguar Health Inc*s business model revolves around developing and commercializing natural, plant-based products for human and animal health. They aim to provide innovative solutions utilizing their scientific expertise in the development of novel medicines and consumer healthcare products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 643.311 mill. $ 10.140 mill. $ -38.872 mill. 159 mill. - Y/Y 19.22 %
Market Cap. Revenues TTM Net Income TTM

$ 643.311 mill.


$ 10.140 mill.


$ -38.872 mill.

Employees Shares Outstanding P/E

-


159 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 19.22 %


MRQ Y/Y - %



BMEA

$5.64

$-7.6000 -57.40%
Last 30 Days


BMEA

$5.64

$-7.6000 -57.40%



Biomea Fusion Inc

Biomea Fusion Inc stock went down -57.40% during the last 30 days.


Biomea Fusion Inc operates on a business model focused on the development of precision medicine for cancer treatments. They leverage advanced genomic technologies to identify and understand specific gene fusions that drive cancer growth. By developing targeted therapies, they aim to improve patient outcomes and revolutionize cancer treatment.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 201.088 mill. $ - mill. $ -107.685 mill. 36 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 201.088 mill.


$ - mill.


$ -107.685 mill.

Employees Shares Outstanding P/E

33


36 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SNSE

$0.6383

$-0.8517 -57.16%
Last 30 Days


SNSE

$0.6383

$-0.8517 -57.16%



Sensei Biotherapeutics Inc

Sensei Biotherapeutics Inc shares went down -57.16% during the last 30 days.


Sensei Biotherapeutics Inc is a biotechnology company that focuses on developing personalized and targeted cancer therapies. They employ a unique approach called ImmunoPhage, which utilizes bacteriophages to specifically target tumor antigens and stimulate an immune response. Their business model revolves around conducting research and clinical trials to bring innovative cancer treatment options to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 16.286 mill. $ - mill. $ -38.919 mill. 26 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 16.286 mill.


$ - mill.


$ -38.919 mill.

Employees Shares Outstanding P/E

-


26 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CARA

$0.35

$-0.4100 -53.95%
Last 30 Days


CARA

$0.35

$-0.4100 -53.95%



Cara Therapeutics inc

Cara Therapeutics Inc stock dropped -53.95% during the last 30 days.


Cara Therapeutics Inc operates under a biotechnology business model focused on developing and commercializing innovative therapeutics to address unmet medical needs, particularly in the field of pruritus and pain management. Their approach involves leveraging their proprietary drug development technology to target specific receptors relevant to these conditions and developing novel pharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 19.106 mill. $ 16.938 mill. $ -122.544 mill. 55 mill. - Y/Y -65.37 %
Market Cap. Revenues TTM Net Income TTM

$ 19.106 mill.


$ 16.938 mill.


$ -122.544 mill.

Employees Shares Outstanding P/E

-


55 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -65.37 %


MRQ Y/Y - %



EQ

$0.713

$-0.8270 -53.70%
Last 30 Days


EQ

$0.713

$-0.8270 -53.70%



Equillium Inc

Equillium Inc shares dropped -53.70% during the last 30 days.


Equillium Inc operates on a business model that focuses on developing and commercializing novel treatments for immune and inflammatory disorders by leveraging their expertise in immunology and translational science. They aim to address unmet medical needs through the discovery and development of therapies targeting specific immune pathways.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 24.869 mill. $ 42.632 mill. $ -8.220 mill. 35 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 24.869 mill.


$ 42.632 mill.


$ -8.220 mill.

Employees Shares Outstanding P/E

18,000


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GANX

$1.24

$-1.3800 -52.67%
Last 30 Days


GANX

$1.24

$-1.3800 -52.67%



Gain Therapeutics Inc

Gain Therapeutics Inc shares went down -52.67% during the last 30 days.


Gain Therapeutics inc*s business model revolves around using cutting-edge technology and innovative approaches to identify and develop small molecules that can effectively target and treat rare genetic diseases, such as lysosomal storage disorders and CNS-related disorders. They aim to leverage their expertise in computational drug design and protein structure analysis to discover potential drug candidates, which can then be developed and commercialized for therapeutic purposes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 22.294 mill. $ - mill. $ -21.144 mill. 18 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 22.294 mill.


$ - mill.


$ -21.144 mill.

Employees Shares Outstanding P/E

-


18 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MBIO

$0.13

$-0.1400 -51.85%
Last 30 Days


MBIO

$0.13

$-0.1400 -51.85%



Mustang Bio inc

Mustang Bio Inc stock went down -51.85% during the last 30 days.


Mustang Bio Inc operates on a business model focused on developing advanced therapies for challenging diseases. They primarily engage in research, development, and commercialization of innovative gene and cell therapies. Mustang Bio Inc aims to provide cutting-edge treatments to patients in need by leveraging its expertise in gene editing technologies and strategic partnerships.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.062 mill. $ - mill. $ -70.209 mill. 8 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.062 mill.


$ - mill.


$ -70.209 mill.

Employees Shares Outstanding P/E

330


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GRTX

$0.094

$-0.0960 -50.53%
Last 30 Days


GRTX

$0.094

$-0.0960 -50.53%



Galera Therapeutics Inc

Galera Therapeutics Inc shares dropped -50.53% during the last 30 days.


Galera Therapeutics Inc is a pharmaceutical company that operates under an innovative business model focused on developing transformative therapies to treat cancer. They utilize a combination of in-house research, strategic partnerships, and scientific collaborations to discover, develop, and commercialize novel drug candidates. By leveraging their expertise and a patient-centric approach, Galera Therapeutics aims to revolutionize cancer treatment and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.275 mill. $ - mill. $ -69.683 mill. 45 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4.275 mill.


$ - mill.


$ -69.683 mill.

Employees Shares Outstanding P/E

-


45 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DRMA

$2.5526

$-2.3974 -48.43%
Last 30 Days


DRMA

$2.5526

$-2.3974 -48.43%



Dermata Therapeutics Inc

Dermata Therapeutics Inc stock declined -48.43% during the last 30 days.


Dermata Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing dermatology and skin care products, focusing on innovative treatments for various skin conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.135 mill. $ - mill. $ -8.689 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.135 mill.


$ - mill.


$ -8.689 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ALXO

$8.05

$-6.9700 -46.40%
Last 30 Days


ALXO

$8.05

$-6.9700 -46.40%



Alx Oncology Holdings Inc

Alx Oncology Holdings Inc shares declined -46.40% during the last 30 days.


Alx Oncology Holdings Inc*s business model is centered around the development and commercialization of innovative cancer therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 331.241 mill. $ - mill. $ -146.042 mill. 41 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 331.241 mill.


$ - mill.


$ -146.042 mill.

Employees Shares Outstanding P/E

17


41 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VERU

$0.8133

$-0.6567 -44.67%
Last 30 Days


VERU

$0.8133

$-0.6567 -44.67%



Veru Inc

Veru Inc shares dropped -44.67% during the last 30 days.


Veru Inc operates as a pharmaceutical company primarily focused on developing and commercializing medicines for men*s and women*s health. With a combination of in-house research and partnerships, Veru Inc aims to address unmet medical needs by providing innovative therapies and products. Their business model encompasses both the development of new pharmaceuticals and the marketing and distribution of their existing products in the healthcare market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 119.052 mill. $ 12.291 mill. $ -35.820 mill. 146 mill. - Y/Y -44.15 %
Market Cap. Revenues TTM Net Income TTM

$ 119.052 mill.


$ 12.291 mill.


$ -35.820 mill.

Employees Shares Outstanding P/E

1,300


146 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -44.15 %


MRQ Y/Y - %



GRI

$0.228

$-0.1727 -43.10%
Last 30 Days


GRI

$0.228

$-0.1727 -43.10%



Gri Bio Inc

Gri Bio Inc stock dropped -43.10% during the last 30 days.


Gri Bio Inc*s business model focuses on providing innovative biotechnology solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.941 mill. $ - mill. $ -12.528 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.941 mill.


$ - mill.


$ -12.528 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GTHX

$2.78

$-1.9100 -40.72%
Last 30 Days


GTHX

$2.78

$-1.9100 -40.72%



G1 Therapeutics Inc

G1 Therapeutics Inc shares declined -40.72% during the last 30 days.


G1 Therapeutics Inc is a biopharmaceutical company that operates under a research and development business model. They focus on discovering, developing, and commercializing novel therapies to address unmet needs in cancer treatment, with a strong emphasis on targeting specific cellular processes. Their business model involves conducting preclinical and clinical trials, obtaining regulatory approvals, and collaborating with strategic partners to bring their innovative drugs to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 145.037 mill. $ 84.041 mill. $ -30.591 mill. 52 mill. - Y/Y 11.82 %
Market Cap. Revenues TTM Net Income TTM

$ 145.037 mill.


$ 84.041 mill.


$ -30.591 mill.

Employees Shares Outstanding P/E

-


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 11.82 %


MRQ Y/Y - %



EYEN

$0.6309

$-0.4291 -40.48%
Last 30 Days


EYEN

$0.6309

$-0.4291 -40.48%



Eyenovia inc

Eyenovia Inc stock declined -40.48% during the last 30 days.


Eyenovia Inc*s business model revolves around developing and commercializing innovative ophthalmic products utilizing its proprietary microfluidic ejection technology. The company aims to enhance treatment options for eye diseases and conditions by delivering more precise and targeted ocular therapeutics. Eyenovia focuses on creating user-friendly, high-precision, and cost-effective eye droppers to improve patient compliance and overall treatment outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 29.404 mill. $ 0.009 mill. $ -32.444 mill. 47 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 29.404 mill.


$ 0.009 mill.


$ -32.444 mill.

Employees Shares Outstanding P/E

7


47 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VIRI

$0.2382

$-0.1618 -40.45%
Last 30 Days


VIRI

$0.2382

$-0.1618 -40.45%



Virios Therapeutics inc

Virios Therapeutics Inc stock went down -40.45% during the last 30 days.


Virios Therapeutics* business model revolves around developing and commercializing innovative therapies for the treatment of human diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.587 mill. $ - mill. $ -4.012 mill. 19 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4.587 mill.


$ - mill.


$ -4.012 mill.

Employees Shares Outstanding P/E

-


19 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



UNCY

$0.6489

$-0.4311 -39.92%
Last 30 Days


UNCY

$0.6489

$-0.4311 -39.92%



Unicycive Therapeutics Inc

Unicycive Therapeutics Inc shares went down -39.92% during the last 30 days.


Unicycive Therapeutics Inc*s business model involves developing and commercializing therapeutic solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 21.176 mill. $ - mill. $ -28.074 mill. 33 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 21.176 mill.


$ - mill.


$ -28.074 mill.

Employees Shares Outstanding P/E

-


33 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CDT

$1.8

$-1.1700 -39.39%
Last 30 Days


CDT

$1.8

$-1.1700 -39.39%



Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc shares went down -39.39% during the last 30 days.


Conduit Pharmaceuticals Inc*s business model revolves around the development and commercialization of pharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 132.893 mill. $ - mill. $ -4.207 mill. 74 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 132.893 mill.


$ - mill.


$ -4.207 mill.

Employees Shares Outstanding P/E

-


74 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



THAR

$3.35

$-2.0710 -38.20%
Last 30 Days


THAR

$3.35

$-2.0710 -38.20%



Tharimmune Inc

Tharimmune Inc shares went down -38.20% during the last 30 days.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 38.572 mill. $ - mill. $ -8.958 mill. 12 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 38.572 mill.


$ - mill.


$ -8.958 mill.

Employees Shares Outstanding P/E

-


12 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HOWL

$3.01

$-1.8400 -37.94%
Last 30 Days


HOWL

$3.01

$-1.8400 -37.94%



Werewolf Therapeutics Inc

Werewolf Therapeutics Inc stock went down -37.94% during the last 30 days.


Werewolf Therapeutics Inc operates with a business model focused on utilizing innovative technologies to develop therapies targeting cancer using immune cell activation.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 125.238 mill. $ 16.221 mill. $ -41.579 mill. 42 mill. - Y/Y -83.38 %
Market Cap. Revenues TTM Net Income TTM

$ 125.238 mill.


$ 16.221 mill.


$ -41.579 mill.

Employees Shares Outstanding P/E

-


42 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -83.38 %


MRQ Y/Y - %



NBTX

$4.6

$-2.7100 -37.07%
Last 30 Days


NBTX

$4.6

$-2.7100 -37.07%



Nanobiotix S a

Nanobiotix S A shares declined -37.07% during the last 30 days.


Nanobiotix S is a company that operates in the field of nanomedicine and innovative therapeutic solutions. Their business model revolves around the development and commercialization of nanotechnology-based products for cancer treatment. They aim to leverage their proprietary technology to deliver targeted and optimized treatments, potentially improving patient outcomes and transforming cancer therapy.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 169.093 mill. $ 40.552 mill. $ -44.464 mill. 37 mill. - Y/Y 658.10 %
Market Cap. Revenues TTM Net Income TTM

$ 169.093 mill.


$ 40.552 mill.


$ -44.464 mill.

Employees Shares Outstanding P/E

-


37 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 658.10 %


MRQ Y/Y - %



EFTR

$1.25

$-0.7300 -36.87%
Last 30 Days


EFTR

$1.25

$-0.7300 -36.87%



Effector Therapeutics Inc

Effector Therapeutics Inc stock went down -36.87% during the last 30 days.


Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.088 mill. $ - mill. $ -35.941 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.088 mill.


$ - mill.


$ -35.941 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NKTR

$1.17

$-0.6600 -36.07%
Last 30 Days


NKTR

$1.17

$-0.6600 -36.07%



Nektar Therapeutics

Nektar Therapeutics shares dropped -36.07% during the last 30 days.


Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company*s approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 222.775 mill. $ 88.260 mill. $ -293.665 mill. 190 mill. - Y/Y 2.20 %
Market Cap. Revenues TTM Net Income TTM

$ 222.775 mill.


$ 88.260 mill.


$ -293.665 mill.

Employees Shares Outstanding P/E

725


190 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 2.20 %


MRQ Y/Y - %



QLGN

$0.199

$-0.1110 -35.81%
Last 30 Days


QLGN

$0.199

$-0.1110 -35.81%



Qualigen Therapeutics Inc

Qualigen Therapeutics Inc stock declined -35.81% during the last 30 days.


Qualigen Therapeutics Inc*s business model revolves around the development, manufacturing, and commercialization of novel therapeutics and diagnostic technologies aimed at improving patient outcomes, utilizing their broad intellectual property portfolio and strategic partnerships. They focus on bringing innovative solutions to market through targeted research and development efforts, while also seeking collaborations to maximize the impact of their products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.005 mill. $ - mill. $ -19.841 mill. 5 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.005 mill.


$ - mill.


$ -19.841 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NTRP

$1.72

$-0.9500 -35.58%
Last 30 Days


NTRP

$1.72

$-0.9500 -35.58%



Neurotrope inc

Neurotrope Inc shares went down -35.58% during the last 30 days.


Neurotrope Inc is a biopharmaceutical company that primarily focuses on the development and commercialization of therapeutic treatments for neurodegenerative disorders by targeting specific molecular pathways. Their business model involves conducting research, acquiring intellectual property rights, and collaborating with scientific and medical experts to advance their drug candidates through clinical trials and potentially bring them to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 40.894 mill. $ - mill. $ 12.353 mill. 24 mill. 172.60 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 40.894 mill.


$ - mill.


$ 12.353 mill.

Employees Shares Outstanding P/E

-


24 mill.


172.60

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 11.64 %



GNLX

$2.36

$-1.2800 -35.16%
Last 30 Days


GNLX

$2.36

$-1.2800 -35.16%



Genelux Corporation

Genelux Corporation stock declined -35.16% during the last 30 days.


Genelux Corporation*s business model revolves around the development and commercialization of innovative genetic-based therapies and technologies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 57.570 mill. $ - mill. $ -28.297 mill. 24 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 57.570 mill.


$ - mill.


$ -28.297 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PRFX

$0.52

$-0.2800 -35.00%
Last 30 Days


PRFX

$0.52

$-0.2800 -35.00%



Painreform Ltd

Painreform Ltd stock declined -35.00% during the last 30 days.


Painreform Ltd operates under a business model focused on developing and commercializing innovative pharmaceutical solutions for pain management. Their approach involves creating novel drug formulations and delivery systems to improve the efficacy, safety, and patient experience in treating acute and chronic pain.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.544 mill. $ - mill. $ -8.792 mill. 11 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5.544 mill.


$ - mill.


$ -8.792 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



XCUR

$0.3302

$-0.1698 -33.96%
Last 30 Days


XCUR

$0.3302

$-0.1698 -33.96%



Exicure Inc

Exicure Inc stock declined -33.96% during the last 30 days.


Exicure Inc operates on a business model focused on developing and commercializing transformative gene therapy drugs utilizing its proprietary spherical nucleic acid (SNA) technology. The company aims to leverage its platform to create therapeutic solutions for various diseases by delivering genetic medicines directly to cells. By collaborating with partners or independently, Exicure Inc aims to advance its pipeline and ultimately bring innovative treatments to the market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.647 mill. $ - mill. $ -16.914 mill. 8 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2.647 mill.


$ - mill.


$ -16.914 mill.

Employees Shares Outstanding P/E

-


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BTAI

$1.37

$-0.6900 -33.50%
Last 30 Days


BTAI

$1.37

$-0.6900 -33.50%



Bioxcel Therapeutics Inc

Bioxcel Therapeutics Inc stock declined -33.50% during the last 30 days.


BioXcel Therapeutics Inc. is a biopharmaceutical company that operates using an innovative business model. They utilize artificial intelligence (AI) and big data analytics to identify and develop novel therapies for targeted diseases with unmet medical needs. This approach allows them to leverage data-driven insights to expedite drug discovery and development, potentially increasing the efficiency and success rate of their drug candidates.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 42.289 mill. $ 1.756 mill. $ -153.048 mill. 31 mill. - Y/Y 182.52 %
Market Cap. Revenues TTM Net Income TTM

$ 42.289 mill.


$ 1.756 mill.


$ -153.048 mill.

Employees Shares Outstanding P/E

51


31 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 182.52 %


MRQ Y/Y - %



VKTX

$52.02

$-25.9900 -33.32%
Last 30 Days


VKTX

$52.02

$-25.9900 -33.32%



Viking Therapeutics Inc

Viking Therapeutics Inc shares declined -33.32% during the last 30 days.


Viking Therapeutics Inc is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,193.989 mill. $ - mill. $ -80.849 mill. 100 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,193.989 mill.


$ - mill.


$ -80.849 mill.

Employees Shares Outstanding P/E

11


100 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ATAI

$1.37

$-0.6800 -33.17%
Last 30 Days


ATAI

$1.37

$-0.6800 -33.17%



Atai Life Sciences N v

Atai Life Sciences N V shares dropped -33.17% during the last 30 days.


Atai Life Sciences Nv is a biotech company focused on developing innovative treatments for mental health disorders. They utilize a multi-disciplinary approach that combines scientific research, clinical trials, and partnerships to accelerate the discovery and development of psychedelic medicines. Using a patient-centric approach, Atai aims to address unmet needs in the mental health space and improve the lives of individuals suffering from these conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 243.265 mill. $ 0.335 mill. $ -71.403 mill. 178 mill. - Y/Y 262.50 %
Market Cap. Revenues TTM Net Income TTM

$ 243.265 mill.


$ 0.335 mill.


$ -71.403 mill.

Employees Shares Outstanding P/E

-


178 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 262.50 %


MRQ Y/Y - %



PBYI

$3.11

$-1.5400 -33.12%
Last 30 Days


PBYI

$3.11

$-1.5400 -33.12%



Puma Biotechnology Inc

Puma Biotechnology Inc shares declined -33.12% during the last 30 days.


Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 149.869 mill. $ 207.225 mill. $ 4.508 mill. 48 mill. 31.10 Y/Y -33.36 %
Market Cap. Revenues TTM Net Income TTM

$ 149.869 mill.


$ 207.225 mill.


$ 4.508 mill.

Employees Shares Outstanding P/E

460


48 mill.


31.10

Revenue Growth Income Growth

MRQ Y/Y -33.36 %


MRQ Y/Y - %



ALLR

$0.4549

$-0.2251 -33.10%
Last 30 Days


ALLR

$0.4549

$-0.2251 -33.10%



Allarity Therapeutics Inc

Allarity Therapeutics Inc stock declined -33.10% during the last 30 days.


Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.056 mill. $ - mill. $ -20.698 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.056 mill.


$ - mill.


$ -20.698 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HUGE

$0.2145

$-0.1055 -32.97%
Last 30 Days


HUGE

$0.2145

$-0.1055 -32.97%



Fsd Pharma Inc

Fsd Pharma Inc stock declined -32.97% during the last 30 days.


Fsd Pharma Inc*s business model is centered around the development and production of pharmaceutical-grade cannabis products. The company aims to leverage its in-house cultivation facility, research and development capabilities, and strategic partnerships to create innovative cannabis-based therapies for various medical conditions. Fsd Pharma focuses on pursuing licensing and acquisition opportunities to expand its presence in the global cannabis market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 4.556 mill. $ -17.902 mill. - mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 4.556 mill.


$ -17.902 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ANVS

$5.85

$-2.8700 -32.91%
Last 30 Days


ANVS

$5.85

$-2.8700 -32.91%



Annovis Bio Inc

Annovis Bio Inc stock went down -32.91% during the last 30 days.


Annovis Bio Inc*s business model revolves around developing novel therapeutics to treat neurodegenerative diseases, including Alzheimer*s disease, Parkinson*s disease, and ALS (amyotrophic lateral sclerosis). They focus on identifying and targeting multiple disease pathways simultaneously to address the complex nature of these disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 63.325 mill. $ - mill. $ -47.534 mill. 11 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 63.325 mill.


$ - mill.


$ -47.534 mill.

Employees Shares Outstanding P/E

812


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MRVI

$7.52

$-3.6800 -32.86%
Last 30 Days


MRVI

$7.52

$-3.6800 -32.86%



Maravai Lifesciences Holdings Inc

Maravai Lifesciences Holdings Inc stock declined -32.86% during the last 30 days.


Maravai Lifesciences Holdings Inc*s business model revolves around providing integrated solutions for the development and manufacturing of biopharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 995.144 mill. $ 278.983 mill. $ -51.073 mill. 132 mill. - Y/Y -68.65 %
Market Cap. Revenues TTM Net Income TTM

$ 995.144 mill.


$ 278.983 mill.


$ -51.073 mill.

Employees Shares Outstanding P/E

1,400


132 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -68.65 %


MRQ Y/Y - %



ME

$0.3964

$-0.1886 -32.24%
Last 30 Days


ME

$0.3964

$-0.1886 -32.24%



23andme Holding Co

23andme Holding Co shares dropped -32.24% during the last 30 days.


23andMe Holding Co operates as a direct-to-consumer genetic testing company. Their business model primarily revolves around selling DNA testing kits to individuals, who can then provide a saliva sample and receive reports on their genetic ancestry, health predispositions, and other genetic traits. The company generates revenue by charging customers for the testing kits, as well as offering additional subscription-based services for ongoing access to updated reports and insights.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 188.772 mill. $ 219.377 mill. $ -666.704 mill. 476 mill. - Y/Y -29.60 %
Market Cap. Revenues TTM Net Income TTM

$ 188.772 mill.


$ 219.377 mill.


$ -666.704 mill.

Employees Shares Outstanding P/E

700


476 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -29.60 %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com